( M.D. The University of Tokushima ...)Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop,Health

M.D., The University of Tokushima Graduate School of Health Biosciences * Abstract #311; Poster session: Tuesday 26th June, 4:30 p.m. -- Effect of VELCADE Monotherapy and VELCADE Based Regimens on Bone Metabolism in Patients with Relapsed / Refractory Multiple Myeloma * Lead investigator: Evangelos Terpos, M.D., General Airforce Hospital * Abstract #320; Poster session: Tuesday 26th June, 4:30 p.m. -- Cystatin-C: An Early Marker of Renal Impairment and an Independent Predictive Factor for Survival in Multiple Myeloma. Reduction Post VELCADE Therapy * Lead investigator: Evangelos Terpos, M.D., General Airforce Hospital * Abstract #227; Poster session: Tuesday 26th June, 4:30 p.m. -- VELCADE in Renally Impaired Multiple Myeloma Patients * Lead investigator: Jesus San Miguel, M.D., PhD., Hospital Universitario de Salamanca * Abstract #1114; Poster session: Thursday 28th June, 4:30 p.m.

VELCADE Shows Potential in Additional Diseases and in Combination with Emerging Agents

New data will highlight VELCADE efficacy in amyloidosis, a disease of high unmet need, and in combination with new agents such as HSP90-, AKT- and mTOR-inhibitors. Abstract highlights include:

    -- Treatment of Light Chain (AL) Amyloidosis with the Combination of

       VELCADE and Dexamethasone

         * Lead investigator: Efstathios Kastritis, M.D., Alexandra Hospital,

           University of Athens School of Medicine

         * Abstract #913; Poster session: Thursday 28th June, 4:30 p.m.

    -- VELCADE and Tanespimycin in Multiple Myeloma: Pharmacology, Safety and

       Activity in Relapsed / Refractory Patients

         * Lead investigator: Paul Richardson, M.D., Dana-Farber Cancer

           Institute

         * Abstract #610; Poster session: Thursday 28th June, 4:30 p.m.

    -- A Multicenter Phase I
'"/>




Page: 1 2 3 4 5 6 7 8 
Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy
Delivered High Post-Transplant Complete Remission Rate, a Critical
Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced
Complete Remission Rates as High as 54 Percent in Patients With
Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved
Survival Rates as High as 100 Percent in Newly Diagnosed Multiple
Myeloma Patients
4. Study Shows Velcade Plus Doxil Improves Survival in Previously
Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection
Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response
to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox
(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10
Days for Reducing the Risk of Venous Thromboembolism (VTE) in
Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018
Injection
9. Genta Announces Results of Phase 1 Study Using Genasense
Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at
Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta
(Talotrexin) for Injection at The American Association for Cancer
Research Annual Meeting